Literature DB >> 15059952

Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats.

Morag Young1, John W Funder.   

Abstract

Aldosterone has been thought to act primarily on epithelia to regulate fluid and electrolyte homeostasis. Mineralocorticoid receptors (MR), however, are also expressed in nonepithelial tissues, such as the heart and vascular smooth muscle. Recently, pathophysiological effects of nonepithelial MR activation by aldosterone have been demonstrated in the context of inappropriate mineralocorticoid levels for salt status, including coronary vascular inflammation and cardiac fibrosis. These effects are mostly prevented by the concomitant administration of MR antagonists, but to date, no equivalent studies have determined whether MR blockade can reverse established inflammation and fibrosis. Uninephrectomized rats maintained on 0.9% NaCl solution to drink were treated as follows: group 1 served as controls; group 2 received deoxycorticosterone (DOC; 20 mg/wk) for 4 wk until death, and group 3 received DOC for 8 wk. Group 4 received DOC for 4 wk and no steroid from wk 5-8; group 5 received DOC for 8 wk and eplerenone in their chow during wk 5-8. DOC progressively raised cardiac collagen accumulation at 4 and 8 wk. Rats given DOC for 4 wk and killed at 8 wk showed levels of fibrosis identical to those in animals killed at 4 wk, i.e. persistently elevated above control values. Rats given DOC for 8 wk and eplerenone for the second half of the period showed cardiac collagen levels indistinguishable from control values. Values for inflammatory marker and NAD(P)H oxidase subunit expression in coronary vessels showed a similar pattern of response, with minor variation. Thus, MR antagonists do not only prevent cardiac fibrosis, but also reverse cardiac fibrosis once it is established. In addition, the continuing vascular inflammatory response and fibrosis after DOC withdrawal (group 4) support a role for activation of vascular MR by endogenous glucocorticoids in the context of tissue damage and generation of reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059952     DOI: 10.1210/en.2004-0005

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

Review 1.  Primary aldosteronism and salt.

Authors:  John W Funder
Journal:  Pflugers Arch       Date:  2014-12-13       Impact factor: 3.657

Review 2.  Hypertension and the expanding role of aldosterone.

Authors:  Scott M Mackenzie; John Connell
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

Review 3.  Aldosterone: effects on the kidney and cardiovascular system.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

Review 4.  Pharmacology of Aldosterone and the Effects of Mineralocorticoid Receptor Blockade on Cardiovascular Systems.

Authors:  Shusuke Yagi; Masashi Akaike; Ken-Ichi Aihara; Daiju Fukuda; Masayoshi Ishida; Takayuki Ise; Toshiyuki Niki; Yuka Sumitomo-Ueda; Koji Yamaguchi; Takashi Iwase; Yoshio Taketani; Hirotsugu Yamada; Takeshi Soeki; Tetsuzo Wakatsuki; Michio Shimabukuro; Masataka Sata
Journal:  Acta Cardiol Sin       Date:  2013-05       Impact factor: 2.672

5.  Are macrophages the foot soldiers in the war waged by aldosterone against the heart?

Authors:  Anne M Dorrance
Journal:  Hypertension       Date:  2009-07-27       Impact factor: 10.190

6.  Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.

Authors:  William B Lea; Eun Soo Kwak; James M Luther; Susan M Fowler; Zuofei Wang; Ji Ma; Agnes B Fogo; Nancy J Brown
Journal:  Kidney Int       Date:  2009-02-18       Impact factor: 10.612

7.  Use of phage display to identify novel mineralocorticoid receptor-interacting proteins.

Authors:  Jun Yang; Peter J Fuller; James Morgan; Hirotaka Shibata; Donald P McDonnell; Colin D Clyne; Morag J Young
Journal:  Mol Endocrinol       Date:  2014-07-07

Review 8.  Should aldosterone blockade be used beyond current indications in heart failure?

Authors:  Marcelle D Smit; Isabelle C van Gelder; Michael Böhm; Hans-Ruprecht Neuberger; Dirk J van Veldhuisen
Journal:  Curr Heart Fail Rep       Date:  2009-06

9.  Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

Authors:  Michael Gekle; Claudia Grossmann
Journal:  Pflugers Arch       Date:  2008-11-19       Impact factor: 3.657

10.  Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.

Authors:  Rosemeire M Kanashiro-Takeuchi; Bettina Heidecker; Guillaume Lamirault; Jennifer W Dharamsi; Joshua M Hare
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.